A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

May 17, 2024

Study Completion Date

May 17, 2024

Conditions

Solid TumorNeoplasmsMalignant Tumor

Interventions

DRUG

ES102

The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)

DRUG

JS001

JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.

Trial Locations (1)

Jilin Cancer Hospital, Changchun

All Listed Sponsors

collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Elpiscience Biopharma, Ltd.

INDUSTRY

NCT04991506 - A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter